Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Current Leases: 2012-2025

Historic Current Leases for Arrowhead Pharmaceuticals (ARWR) over the last 10 years, with Sep 2025 value amounting to $7.3 million.

  • Arrowhead Pharmaceuticals' Current Leases rose 14.93% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 14.93%. This contributed to the annual value of $7.3 million for FY2025, which is 14.93% up from last year.
  • Arrowhead Pharmaceuticals' Current Leases amounted to $7.3 million in FY2025, which was up 14.93% from $6.3 million recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Current Leases ranged from a high of $10.6 million in FY2023 and a low of $2.2 million during FY2021.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Current Leases value was $7.3 million (recorded in 2025), while the average stood at $8.1 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Current Leases skyrocketed by 280.51% in 2023, and later crashed by 39.96% in 2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Current Leases (Yearly) stood at $2.2 million in 2021, then climbed by 23.38% to $2.8 million in 2022, then skyrocketed by 280.51% to $10.6 million in 2023, then plummeted by 39.96% to $6.3 million in 2024, then grew by 14.93% to $7.3 million in 2025.